Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints
Endo admits to marketing its post-herpetic neuralgia pain drug Lidoderm for unapproved uses in a $192.7 million settlement; National Economic Council Director says there is “a sweet spot for bipartisan compromise” on patent troll bills introduced in the House and Senate.
You may also be interested in...
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
Amendments make things a little better for drug firms as attention now shifts to the Senate version.
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.